Neural Cadherin Plays Distinct Roles for Neuronal Survival and Axon Growth Under Different Regenerative Conditions
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only. -
Epha Receptors and Ephrin-A Ligands Are Upregulated by Monocytic
Mukai et al. BMC Cell Biology (2017) 18:28 DOI 10.1186/s12860-017-0144-x RESEARCHARTICLE Open Access EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/ maturation and promote cell adhesion and protrusion formation in HL60 monocytes Midori Mukai, Norihiko Suruga, Noritaka Saeki and Kazushige Ogawa* Abstract Background: Eph signaling is known to induce contrasting cell behaviors such as promoting and inhibiting cell adhesion/ spreading by altering F-actin organization and influencing integrin activities. We have previously demonstrated that EphA2 stimulation by ephrin-A1 promotes cell adhesion through interaction with integrins and integrin ligands in two monocyte/ macrophage cell lines. Although mature mononuclear leukocytes express several members of the EphA/ephrin-A subclass, their expression has not been examined in monocytes undergoing during differentiation and maturation. Results: Using RT-PCR, we have shown that EphA2, ephrin-A1, and ephrin-A2 expression was upregulated in murine bone marrow mononuclear cells during monocyte maturation. Moreover, EphA2 and EphA4 expression was induced, and ephrin-A4 expression was upregulated, in a human promyelocytic leukemia cell line, HL60, along with monocyte differentiation toward the classical CD14++CD16− monocyte subset. Using RT-PCR and flow cytometry, we have also shown that expression levels of αL, αM, αX, and β2 integrin subunits were upregulated in HL60 cells along with monocyte differentiation while those of α4, α5, α6, and β1 subunits were unchanged. Using a cell attachment stripe assay, we have shown that stimulation by EphA as well as ephrin-A, likely promoted adhesion to an integrin ligand- coated surface in HL60 monocytes. Moreover, EphA and ephrin-A stimulation likely promoted the formation of protrusions in HL60 monocytes. -
Anti-ITGAE (GW21349)
3050 Spruce Street, Saint Louis, MO 63103 USA Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757 email: [email protected] Product Information Anti-ITGAE antibody produced in chicken, affinity isolated antibody Catalog Number GW21349 Formerly listed as GenWay Catalog Number 15-288-21349, Integrin alpha-E Antibody. – Storage Temperature Store at 20 °C The product is a clear, colorless solution in phosphate buffered saline, pH 7.2, containing 0.02% sodium azide. Synonyms: Integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide), Mucosal Species Reactivity: Human lymphocyte 1 antigen; HML-1 antigen; Integrin alpha-IEL; Tested Applications: WB CD103 antigen Recommended Dilutions: Recommended starting dilution Product Description for Western blot analysis is 1:500, for tissue or cell staining Integrin alpha-E/beta-7 is a receptor for E-cadherin. It 1:200. mediates adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers. Note: Optimal concentrations and conditions for each application should be determined by the user. NCBI Accession number: NP_002199.2 Swiss Prot Accession number: P38570 Precautions and Disclaimer This product is for R&D use only, not for drug, household, or Gene Information: Human .. ITGAE (3682) other uses. Due to the sodium azide content a material Immunogen: Recombinant protein Integrin, alpha E (anti- safety data sheet (MSDS) for this product has been sent to gen CD103, human mucosal lymphocyte antigen 1; alpha the attention of the safety officer of your institution. Please polypeptide) consult the Material Safety Data Sheet for information regarding hazards and safe handling practices. Immunogen Sequence: GI # 6007851, sequence 773 - 817 Storage/Stability For continuous use, store at 2–8 °C for up to one week. -
Crosstalk Between Integrin and Receptor Tyrosine Kinase Signaling in Breast Carcinoma Progression
BMB reports Mini Review Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression Young Hwa Soung, John L. Clifford & Jun Chung* Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130 This review explored the mechanism of breast carcinoma pro- cancer originates from breast epithelial cells that are trans- gression by focusing on integrins and receptor tyrosine kinases formed into metastatic carcinomas. Metastatic potential and re- (or growth factor receptors). While the primary role of integrins sponsiveness to treatment vary depending on the expression of was previously thought to be solely as mediators of adhesive hormone receptors such as estrogen receptor and progesterone interactions between cells and extracellular matrices, it is now receptor (5), RTKs such as ErbB-2, epidermal growth factor re- believed that integrins also regulate signaling pathways that ceptor (EGFR), and hepatocyte growth factor receptor, c-Met control cancer cell growth, survival, and invasion. A large (6), and integrins (7). Major integrins expressed on breast epi- body of evidence suggests that the cooperation between in- thelial cells include α2β1, α3β1, αvβ3, αvβ5, αvβ6, α5β1, tegrin and receptor tyrosine kinase signaling regulates certain α6β1, and α6β4 (7). Among these, this review focuses on signaling functions that are important for cancer progression. αvβ3, α5β1, and α6β4, all of which are upregulated in in- Recent developments on the crosstalk between integrins and vasive breast carcinoma and have well established relation- receptor tyrosine kinases, and its implication in mammary tu- ships with RTKs (8). These integrins serve as receptors for vi- mor progression, are discussed. -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
1 Adhesion and Growth Factor Receptor Crosstalk Mechanisms
Adhesion and Growth Factor Receptor Crosstalk Mechanisms Controlling Cell Migration Joanna R. Thomas1,2, Nikki R. Paul3, Mark R. Morgan1† 1. Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, L69 3BX, UK. 2. Present Address: Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA 3. Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK. † Corresponding author Correspondence to: Dr Mark R. Morgan, PhD, Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, L69 3BX, UK. Tel: [+44](0)151-795-4992 / e-mail: [email protected] / Twitter: @M_MorganLab Keywords: Integrin, Growth Factor Receptor, Syndecan, Migration, Adhesion, Trafficking, Endocytosis, Signalling, Abbreviations: AKT - AKT Serine/Threonine Kinase c-MET - Hepatocyte growth factor receptor ECM - Extracellular matrix EGF - Epidermal growth factor FAK - Focal adhesion kinase EGFR - Epidermal growth factor receptor FAK - Focal Adhesion Kinase FGFR - Fibroblast growth factor receptor GFR - Growth factor receptor HSPG - heparan sulfate proteoglycans IAC - Integrin-associated complex MAPK - Mitogen activated protein kinase PI3K - Phosphoinositide 3-kinase PKC - Protein kinase C RCP - Rab-coupling protein RTK - Receptor tyrosine kinase TCPTP - T-cell protein tyrosine phosphatase / PTPN2 TGFβ - Transforming growth factor β TGFβR2 - Transforming growth factor β receptor 2 VEGFR2 - Vascular endothelial growth factor receptor 1 Abstract Cell migration requires cells to sense and interpret an array of extracellular signals to precisely co-ordinate adhesion dynamics, local application of mechanical force, polarity signalling and cytoskeletal dynamics. Adhesion receptors and growth factor receptors exhibit functional and signalling characteristics that individually contribute to cell migration. Integrins transmit bidirectional mechanical forces and transduce long-range intracellular signals. -
5 and 2 Integrin Gene Transfers Mimic the PDGF-B–Induced Transformed
0023-6837/01/8109-1263$03.00/0 LABORATORY INVESTIGATION Vol. 81, No. 9, p. 1263, 2001 Copyright © 2001 by The United States and Canadian Academy of Pathology, Inc. Printed in U.S.A. ␣5 and ␣2 Integrin Gene Transfers Mimic the PDGF-B–Induced Transformed Phenotype of Fibroblasts in Human Skin Mark Nesbit, Helmut Schaider, Carola Berking, Daw-Tsun Shih, Mei-Yu Hsu, Michelle McBrian, Timothy M. Crombleholme, Rosalie Elenitsas, Clayton Buck, and Meenhard Herlyn The Wistar Institute (MN, HS, CB, D-TS, M-YH, MM, CB, MH), Philadelphia; Department of Surgery (TMC), The Children’s Hospital of Philadelphia, Philadelphia; and Department of Dermatology (RE), University of Pennsylvania, Philadelphia, Pennsylvania SUMMARY: Platelet-derived growth factor (PDGF)-B is a proto-oncogene capable of transforming fibroblasts. Using adenoviral vectors, we tested whether endogenous PDGF-B expression in human skin xenotransplants leads to changes in the expression of ␣5 and ␣2 integrin subunits and whether integrin overexpression leads to PDGF-related changes in the skin. In vitro, transduction of fibroblasts with PDGF-B or the integrin ␣5 subunit stimulated multilayered growth and spindle-type morphology, both markers of mesenchymal cell transformation. In vivo, PDGF-B transduction of the human dermis was associated with up-regulation of collagen and fibronectin synthesis, increases in ␣5 and ␣2 integrin subunit expression, vessel formation, and proliferation of fibroblasts, keratinocytes, and pericytes. A similar stromal response was induced when ␣5 and ␣2 integrin subunits were overexpressed in the human dermis, suggesting that integrins play a major role in the induction of a transformed phenotype of fibroblasts by PDGF-B. -
Metabolic Imaging Allows Early Prediction of Response to Vandetanib
Metabolic Imaging Allows Early Prediction of Response to Vandetanib Martin A. Walter1,2,MatthiasR.Benz2,IsabelJ.Hildebrandt2, Rachel E. Laing2, Verena Hartung3, Robert D. Damoiseaux4, Andreas Bockisch3, Michael E. Phelps2,JohannesCzernin2, and Wolfgang A. Weber2,5 1Institute of Nuclear Medicine, University Hospital, Bern, Switzerland; 2Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; 3Institute of Nuclear Medicine, University Hospital, Essen, Germany; 4Molecular Shared Screening Resources, UCLA, Los Angeles, California; and 5Department of Nuclear Medicine, University Hospital, Freiburg, Germany The RET (rearranged-during-transfection protein) protoonco- The RET (rearranged-during-transfection protein) proto- gene triggers multiple intracellular signaling cascades regulat- oncogene, located on chromosome 10q11.2, encodes for ing cell cycle progression and cellular metabolism. We therefore a tyrosine kinase of the cadherin superfamily that activates hypothesized that metabolic imaging could allow noninvasive detection of response to the RET inhibitor vandetanib in vivo. multiple intracellular signaling cascades regulating cell sur- Methods: The effects of vandetanib treatment on the full- vival, differentiation, proliferation, migration, and chemo- genome expression and the metabolic profile were analyzed taxis (1). Gain-of-function mutations in the RET gene result in the human medullary thyroid cancer cell line TT. In vitro, tran- in uncontrolled growth and cause human cancers and scriptional changes of pathways regulating cell cycle progres- cancer syndromes, such as Hu¨rthle cell cancer, sporadic sion and glucose, dopa, and thymidine metabolism were papillary thyroid carcinoma, familial medullary thyroid correlated to the results of cell cycle analysis and the uptake of 3H-deoxyglucose, 3H-3,4-dihydroxy-L-phenylalanine, and carcinoma, and multiple endocrine neoplasia types 2A 3H-thymidine under vandetanib treatment. -
Integrin Signaling Revisited
466 Review TRENDS in Cell Biology Vol.11 No.12 December 2001 Integrin signaling revisited Martin A. Schwartz Adhesion to the extracellular matrix (ECM) is a crucial regulator of cell function, appear to be downstream of FAK and to contribute to and it is now well established that signaling by integrins mediates many of cell migration12,13. The adaptor protein p130cas also these effects. Ten years of research has seen integrin signaling advance on binds to FAK and has been linked to activation of the many fronts towards a molecular understanding of the control mechanisms. small GTPase Rac to promote motility. This diversity of Most striking is the merger with studies of other receptors, the cytoskeleton downstream pathways that converge on cell migration and mechanical forces within the general field of signaling networks. suggests that FAK is a central coordinator of this process. FAK has also been implicated in cell-cycle When I wrote a Trends in Cell Biology review on regulation through activation of both the Erk and integrin signaling in 19921, a 3000-word article could JNK pathways. And FAK plays an important role in cover the entire subject without omitting any key mediating integrin-dependent cell survival, possibly references. In the year 2000 alone, a literature search through phosphoinositide (PI) 3-kinase or JNK7,8,14,15. on ‘integrin’ plus ‘signal transduction’ yielded 480 Multiple physical associations of FAK with references. Given the impossibility of covering more other signaling molecules appear to mediate these than a sliver of what’s been written, I have chosen to multiple effector pathways. -
Integrin-Mediated Action of Insulin-Like Growth Factor Binding Protein-2 in Tumor Cells
859 Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells B S Schütt, M Langkamp, U Rauschnabel1, M B Ranke and M W Elmlinger Pediatric Endocrinology Section, University Children’s Hospital, 72076 Tuebingen, Germany and 1Olga Hospital, 70176 Stuttgart, Germany (Requests for offprints should be addressed to Martin W Elmlinger, Pediatric Endocrinology Section, Children’s Hospital, Hoppe-Seyler-Strasse 1, D-72076 Tuebingen/Germany; Email: [email protected]) (B S Schütt and M Langkamp contributed equally to this work) Abstract The neoplastic production of the insulin-like growth factor binding protein (IGFBP)-2 often correlates with tumor malignancy and aggressiveness. Since IGFBP-2 contains an RGD motif in its C-terminus, it was hypothesized that this protein may act independently of IGF on tumor cells through integrins. To investigate this, integrin binding, intracellular signaling and the impact of IGFBP-2 on cell adhesion and proliferation were examined in two tumor cell lines. In tracer displacement studies, up to 30% of the added 125I-hIGFBP-2 specifically bound to the cells. Bound 125I-hIGFBP-2 was reversibly displaced by IGFBP-2, IGFBP-1 and RGD-(Gly-Arg-Asp)-containing peptides, but not by IGFBP-3, -4, -5, -6 and RGE-(Gly-Arg-Glu)-containing peptides. Blocking with antibodies directed against different integrins and with fibronectin demonstrated that IGFBP-2 cell surface binding is specific for 51-integrin. Incubation of IGFBP-2 with equimolar quantities of IGF-I and IGF-II annihilated RGD-specific binding. IGFBP-2 binding at the cell surface led to dephosphorylation of the focal adhesion-kinase (FAK) of up to 37% (P<0·01), and of the p42/44 MAP-kinases of up to 40% (P<0·01). -
A6b1 Integrin Induces Proteasome-Mediated Cleavage of Erbb2 in Breast Cancer Cells
Oncogene (2003) 22, 831–839 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc a6b1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells Hajime Shimizu*, Takashi Seiki, Makoto Asada, Kentaro Yoshimatsu and Noriyuki Koyama Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan ErbB2 and a6 integrin have been implicated in malignancy more motile phenotype, together with the suppression of of breast cancer cells. Here we have determined the apoptosis (O’Connor et al., 1998; Bachelder et al., 1999; influence of a6b1 integrin on erbB2 signaling in ancho- Vogelmann et al., 1999). In contrast to these results, rage-independent growth, using MDA-MB435 breast decreased expression of integrin subunits, including a2, cancer cells. Firstly, we transfected the cells with erbB2 a3, a5, a6, b1 and b4, has been observed, accompanied cDNA, and isolated cells with high or low levels of a6b1 with the loss of cell polarity and basement membrane, at integrin by cell sorting (a6H-ErbB and a6L-ErbB). We the initial stages of breast cancer progression (Koukou- found that an erbB ligand, heregulin b1, enhanced growth lis et al., 1991; Pignatelli et al., 1991; Natali et al., 1992). activity of a6L-ErbB cells, but not a6H-ErbB cells. Further, several reports described the suppression of Secondly, we established cells expressing a b4 integrin transformed phenotype by enforced expression of deletion mutant (b4-Dcyt), which selectively inhibited integrins. a5b1 expression reduced both in vitro and in a6b1 integrin expression and adhesion to laminin-1. -
Loss of the Nuclear Wnt Pathway Effector TCF7L2 Promotes Migration and Invasion of Human Colorectal Cancer Cells
Oncogene (2020) 39:3893–3909 https://doi.org/10.1038/s41388-020-1259-7 ARTICLE Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells 1,2 1 3 4,5,6 2,5 Janna Wenzel ● Katja Rose ● Elham Bavafaye Haghighi ● Constanze Lamprecht ● Gilles Rauen ● 1 7 3,8,9 1,2,5 Vivien Freihen ● Rebecca Kesselring ● Melanie Boerries ● Andreas Hecht Received: 27 September 2019 / Revised: 3 March 2020 / Accepted: 4 March 2020 / Published online: 20 March 2020 © The Author(s) 2020. This article is published with open access Abstract The transcription factor TCF7L2 is indispensable for intestinal tissue homeostasis where it transmits mitogenic Wnt/ β-Catenin signals in stem and progenitor cells, from which intestinal tumors arise. Yet, TCF7L2 belongs to the most frequently mutated genes in colorectal cancer (CRC), and tumor-suppressive functions of TCF7L2 were proposed. This apparent paradox warrants to clarify the role of TCF7L2 in colorectal carcinogenesis. Here, we investigated TCF7L2 dependence/independence of CRC cells and the cellular and molecular consequences of TCF7L2 loss-of-function. By genome editing we achieved complete TCF7L2 inactivation in several CRC cell lines without loss of viability, showing that fi 1234567890();,: 1234567890();,: CRC cells have widely lost the strict requirement for TCF7L2. TCF7L2 de ciency impaired G1/S progression, reminiscent of the physiological role of TCF7L2. In addition, TCF7L2-negative cells exhibited morphological changes, enhanced migration, invasion, and collagen adhesion, albeit the severity of the phenotypic alterations manifested in a cell-line-specific fashion. To provide a molecular framework for the observed cellular changes, we performed global transcriptome profiling and identified gene-regulatory networks in which TCF7L2 positively regulates the proto-oncogene MYC, while repressing the cell cycle inhibitors CDKN2C/CDKN2D.